Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world, and exhibits heterogeneous characteristics in terms of genomic alterations, expression signature and drug responsivene
RATIONALE: Vandetanib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
In order to analyze the molecular effect of the combination of Notch inhibitors and EGFR inhibitors on resistance to TKI, we performed RNA-seq gene expression profiling of PC9 resistant to Gefitinib c
